Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 356

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082

Type 2 diabetes mellitus

Not yet recruiting

Evaluation of Long-Term Efficacy and Safety of Tirzepatide Versus Intensified Conventional Care in Early Treatment of Type 2 Diabetes in Adults

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Albiglutide

Hypertrophic cardiomyopathy

Not yet recruiting

Effect of oral mavacamten on left ventricular filling pressure in patients with hypertrophic cardiomyopathy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten

HIV infection

Not yet recruiting

Semaglutide for reducing visceral fat in adults with HIV, BMI 25–30 kg/m2 and no diabetes: randomized trial with lifestyle intervention

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa

Chronic lymphocytic leukaemia+2

Not yet recruiting

Study of Ibrutinib Plus Ritonavir in Adults with Chronic Lymphocytic Leukemia, Lymphoplasmacytic Lymphoma, and Mantle Cell Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa

Tislelizumab with drug combination in patients with PD-L1‑high metastatic non‑small cell lung cancer and high tumor burden

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib

Mucormycosis

Not yet recruiting

Efficacy of isavuconazonium sulfate and amphotericin B drug combination for initial treatment of mucormycosis in adults

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B

Pre-eclampsia

Not yet recruiting

Safety and tolerability of rinvecalinase alfa in pregnant women with preterm preeclampsia undergoing expectant management

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Rinvecalinase alfa
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.